|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:3183–424. 2018. View Article : Google Scholar
|
|
2
|
Pastan I and Gottesman M: Multiple-drug
resistance in human cancer. N Engl J Med. 316:1388–1393. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trock BJ, Leonessa F and Clarke R:
Multidrug resistance in breast cancer: A meta-analysis of
MDR1/gp170 expression and its possible functional significance. J
Natl Cancer Inst. 89:917–931. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robey RW, Pluchino KM, Hall MD, Fojo AT,
Bates SE and Gottesman MM: Revisiting the role of ABC transporters
in multidrug-resistant cancer. Nat Rev Cancer. 18:454–464. 2018.
View Article : Google Scholar
|
|
5
|
Battistella C and Klok HA: Reversion of
P-gp-mediated drug resistance in ovarian carcinoma cells with
PHPMA-zosuquidar conjugates. Biomacromolecules. 18:1855–1865. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Vera AA, Gupta P, Lei Z, Liao D,
Narayanan S, Teng Q, Reznik SE and Chen ZS: Immuno-oncology agent
IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1,
ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and
in vivo. Cancer Lett. 442:91–103. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ocaña OH, Córcoles R, Fabra A,
Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A and
Nieto MA: Metastatic colonization requires the repression of the
epithelial-mesenchymal transition inducer Prrx1. Cancer Cell.
22:709–724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi Y, Sawada G, Kurashige J, Uchi
R, Matsumura T, Ueo H, Takano Y, Akiyoshi S, Eguchi H, Sudo T, et
al: Paired related homoeobox 1, a new EMT inducer, is involved in
metastasis and poor prognosis in colorectal cancer. Br J Cancer.
109:307–311. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reichert M, Takano S, Von Burstin J, Kim
SB, Lee JS, Ihida-Stansbury K, Hahn C, Heeg S, Schneider G, Rhim
AD, et al: The Prrx1 homeodomain transcription factor plays a
central role in pancreatic regeneration and carcinogenesis. Genes
Dev. 27:288–300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo J, Fu Z, Wei J, Lu W, Feng J and Zhang
S: PRRX1 promotes epithelial-mesenchymal transition through the
Wnt/β-catenin pathway in gastric cancer. Med Oncol. 32:3932015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marcucci F, Stassi G and Maria RD:
Epithelial-mesenchymal transition: A new target in anticancer drug
discovery. Nat Rev Drug Discov. 15:311–325. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fourier A, Escal J, Bernard E, Lachman I,
Perret-Liaudet A, Leblanc P and Quadrio I: Development of an
automated capillary nano-immunoassay-simple western assay-to
quantify total TDP43 protein in human platelet samples. Anal
Bioanal Chem. 411:267–275. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dahl JA, Jung I, Aanes H, Greggains GD,
Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, et al: Broad
histone H3K4me3 domains in mouse oocytes modulate
maternal-to-zygotic transition. Nature. 537:548–552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maehama T, Taylor GS and Dixon JE: PTEN
and myotubularin: Novel phosphoinositide phosphatases. Annu Rev
Biochem. 70:247–279. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Videira M, Reis RL and Brito MA:
Deconstructing breast cancer cell biology and the mechanisms of
multidrug resistance. Biochim Biophys Acta. 1846:312–325.
2014.PubMed/NCBI
|
|
18
|
Kovalchuk O, Filkowski J, Meservy J,
Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement
of microRNA-451 in resistance of the MCF-7 breast cancer cells to
chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial- mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mallini P, Lennard TWJ, Kirby JA and
Meeson A: Epithelial-to-mesenchymal transition: What is the impact
on breast cancer stem cells and drug resistance. Cancer Treat Rev.
40:341–348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rice AJ, Cortes E, Lachowski D, Cheung
BCH, Karim SA, Morton JP and Del Río Hernández A: Matrix stiffness
induces epithelial-mesenchymal transition and promotes
chemoresistance in pancreatic cancer cells. Oncogenesis.
6:e3522017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Saxena M, Stephens MA, Pathak H and
Rangarajan A: Transcription factors that mediate
epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2:e1792011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin SM, Xia Q, Zhang YQ, Sun AM and Chen
LH: miR-124 regulates radiosensitivity of colorectal cancer cells
by targeting PRRX1. Nan Fang Yi Ke Da Xue Xue Bao. 36:1110–1116.
2016.(In Chinese). PubMed/NCBI
|
|
26
|
Zhu H and Sun G: Loss of PRRX1 induces
epithelial-mesenchymal transition and cancer stem cell-like
properties in A549 cells. Am J Transl Res. 9:1641–1650.
2017.PubMed/NCBI
|
|
27
|
Zhu H, Sun G, Dong J and Fei L: The role
of PRRX1 in the apoptosis of A549 cells induced by cisplatin. Am J
Transl Res. 9:396–402. 2017.PubMed/NCBI
|
|
28
|
Leonard GD, Fojo T and Bates SE: The role
of ABC transporters in clinical practice. Oncologist. 8:411–424.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schinkel AH and Jonker JW: Mammalian drug
efflux transporters of the ATP binding cassette (ABC) family: An
overview. Adv Drug Del Rev. 55:3–29. 2003. View Article : Google Scholar
|
|
30
|
Meng H, Liong M, Xia T, Li Z, Ji Z, Zink
JI and Nel AE: Engineered design of mesoporous silica nanoparticles
to deliver doxorubicin and P-glycoprotein siRNA to overcome drug
resistance in a cancer cell line. ACS Nano. 4:4539–4550. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lv Z, Kong B, Liu X, Jin LY, Dong Q, Li FN
and Wang HB: miR-655 suppresses epithelial-to-mesenchymal
transition by targeting Prrx1 in triple-negative breast cancer. J
Cell Mol Med. 20:864–873. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perumal E, Youn KS, Sun S, Seung-Hyun J,
Suji M, Jieying L and Yeun-Jun C: PTEN inactivation induces
epithelial-mesenchymal transition and metastasis by intranuclear
translocation of β-catenin and snail/slug in non-small cell lung
carcinoma cells. Lung Cancer. 130:25–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan R, Wang Y, Shi M, Xiao Y, Liu L, Liu L
and Guo B: Regulation of PTEN/AKT/FAK pathways by PPARγ impacts on
fibrosis in diabetic nephropathy. J Cell Biochem. Jan 16–2019.(Epub
ahead of print).
|
|
34
|
Gao C, Yuan X, Jiang Z, Gan D, Ding L, Sun
Y, Zhou J, Xu L, Liu Y and Wang G: Regulation of AKT
phosphorylation by GSK3β and PTEN to control chemoresistance in
breast cancer. Breast Cancer Res Treat. 176:291–301. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang L, Lin N and Li Y: The PI3K/AKT
signaling pathway regulates ABCG2 expression and confers resistance
to chemotherapy in human multiple myeloma. Oncol Rep. 41:1678–1690.
2019.PubMed/NCBI
|
|
36
|
Zhang Y, Sui R, Chen Y, Liang H, Shi J and
Piao H: Long noncoding RNA MT1JP inhibits proliferation, invasion,
and migration while promoting apoptosis of glioma cells through the
activation of PTEN/Akt signaling pathway. J Cell Physiol.
234:19553–19564. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen SR, Cai WP, Dai Xj, Guo AS, Chen HP,
Lin GS and Lin RS: Research on miR-126 in glioma targeted
regulation of PTEN/PI3K/Akt and MDM2-p53 pathways. Eur Rev Med
Pharmacol Sci. 23:3461–3470. 2019.PubMed/NCBI
|
|
38
|
Feng H, Zhang Z, Qing X, French SW and Liu
D: miR-186-5p promotes cell growth, migration and invasion of lung
adenocarcinoma by targeting PTEN. Exp Mol Pathol. 108:105–113.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang R, Wang F, Cao H and Yang JY: miR-223
regulates proliferation and apoptosis of IL-22-stimulated HaCat
human keratinocyte cell lines via the PTEN/Akt pathway. Life Sci.
230:28–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
